LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

Inicio・Lista de Acciones・Cara Therapeutics Inc

Cara Therapeutics Inc

Abierto

Sector Salud

0.31 6.9

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.29

Máximo

0.31

Métricas clave
By Trading Economics
Ingresos	-28M
Ventas	-1.9M 3M
BPA	-0.59
Margen de beneficio	-576.079
Empleados	55
EBITDA	-29M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	+212.5 upside

Dividendos
By Dow Jones
Próximas Ganancias	11 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-2.3M 46M
Apertura anterior	-6.59
Cierre anterior	0.31

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

75 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.3145 / 0.36 Soporte y Resistencia

Cara Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2024, 23:42 UTC

Ganancias

Syrah Resources: Vidalia AAM Facility Has Ramped Up Operations

8 sept 2024, 23:41 UTC

Ganancias

Syrah Resources: No Natural Graphite Shipments in Half-Year to Chinese Anode Customers Amid Competition, Oversupply

8 sept 2024, 23:40 UTC

Ganancias

Syrah Resources: Half-Year Balama Production and Sales Decreased Compared With Prior Period

8 sept 2024, 23:37 UTC

Ganancias

Syrah Resources: Half-Year Revenue US$19 Mln Vs US$28.4 Mln in Prior Period

8 sept 2024, 23:37 UTC

Ganancias

Syrah Resources: Half-Year Comprehensive Loss US$63.3 Mln Vs US$37.1 Mln Loss in Prior Period

8 sept 2024, 22:38 UTC

Principales Noticias

Stocks Are Poised to Fall -- Barrons.com

8 sept 2024, 18:40 UTC

Principales Noticias

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- Update

8 sept 2024, 15:24 UTC

Principales Noticias

Boeing Reaches Deal With Biggest Union in Effort to Avoid Strike -- WSJ

8 sept 2024, 13:00 UTC

Principales Noticias

Crypto Plan Creates Potential Conflicts for Trump -- WSJ

8 sept 2024, 09:00 UTC

Principales Noticias

Nvidia Draws Antitrust Scrutiny as Enforcers Signal Early Interest in AI -- WSJ

8 sept 2024, 07:30 UTC

Principales Noticias

Biotechs Are in Focus as Congress Looks to Get Tougher on China -- Barrons.com

8 sept 2024, 01:00 UTC

Principales Noticias

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- WSJ

7 sept 2024, 17:35 UTC

Principales Noticias

Fed Outlook Remains Uncertain After September Cut -- Barrons.com

7 sept 2024, 09:30 UTC

Principales Noticias

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- Heard on the Street -- WSJ

7 sept 2024, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 sept 2024, 04:05 UTC

Principales Noticias

China's Forex Reserves Rose in August as U.S. Dollar Weakened -- WSJ

6 sept 2024, 22:41 UTC

Charlas de Mercado

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept 2024, 21:18 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept 2024, 21:05 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept 2024, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 20:39 UTC

Ganancias

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept 2024, 20:35 UTC

Principales Noticias

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept 2024, 20:34 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept 2024, 20:11 UTC

Principales Noticias

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept 2024, 19:51 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept 2024, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept 2024, 19:14 UTC

Charlas de Mercado

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept 2024, 19:01 UTC

Charlas de Mercado

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept 2024, 18:27 UTC

Principales Noticias

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept 2024, 18:25 UTC

Charlas de Mercado

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

Comparación entre iguales

Cambio de precio

Cara Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

212.5% repunte

Estimación a 12 meses

Media 1 USD 212.5%

Máximo 1 USD

Mínimo 1 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cara Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Cara Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.3145 / 0.36Soporte y Resistencia

Recent bearish events outweigh bullish events.

There are no events.

Sentimiento

By Acuity

75 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Cara Therapeutics Inc

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.